WO2011001169A1 - Use of one or a combination of phyto-cannabinoids in the treatment of epilepsy - Google Patents
Use of one or a combination of phyto-cannabinoids in the treatment of epilepsy Download PDFInfo
- Publication number
- WO2011001169A1 WO2011001169A1 PCT/GB2010/051066 GB2010051066W WO2011001169A1 WO 2011001169 A1 WO2011001169 A1 WO 2011001169A1 GB 2010051066 W GB2010051066 W GB 2010051066W WO 2011001169 A1 WO2011001169 A1 WO 2011001169A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- thcv
- seizures
- cbd
- seizure
- animals
- Prior art date
Links
- 239000003557 cannabinoid Substances 0.000 title claims abstract description 39
- 229940065144 cannabinoids Drugs 0.000 title claims abstract description 24
- 238000011282 treatment Methods 0.000 title claims abstract description 18
- 206010015037 epilepsy Diseases 0.000 title abstract description 17
- 206010010904 Convulsion Diseases 0.000 claims abstract description 216
- ZROLHBHDLIHEMS-UHFFFAOYSA-N Delta9 tetrahydrocannabivarin Natural products C1=C(C)CCC2C(C)(C)OC3=CC(CCC)=CC(O)=C3C21 ZROLHBHDLIHEMS-UHFFFAOYSA-N 0.000 claims abstract description 116
- ZROLHBHDLIHEMS-HUUCEWRRSA-N (6ar,10ar)-6,6,9-trimethyl-3-propyl-6a,7,8,10a-tetrahydrobenzo[c]chromen-1-ol Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCC)=CC(O)=C3[C@@H]21 ZROLHBHDLIHEMS-HUUCEWRRSA-N 0.000 claims abstract description 114
- 229930003827 cannabinoid Natural products 0.000 claims abstract description 33
- 239000000419 plant extract Substances 0.000 claims abstract description 6
- QHMBSVQNZZTUGM-UHFFFAOYSA-N Trans-Cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-UHFFFAOYSA-N 0.000 claims description 83
- 229950011318 cannabidiol Drugs 0.000 claims description 83
- ZTGXAWYVTLUPDT-UHFFFAOYSA-N cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CC=C(C)C1 ZTGXAWYVTLUPDT-UHFFFAOYSA-N 0.000 claims description 83
- PCXRACLQFPRCBB-ZWKOTPCHSA-N dihydrocannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)C)CCC(C)=C1 PCXRACLQFPRCBB-ZWKOTPCHSA-N 0.000 claims description 83
- QHMBSVQNZZTUGM-ZWKOTPCHSA-N cannabidiol Chemical compound OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-ZWKOTPCHSA-N 0.000 claims description 82
- 239000000284 extract Substances 0.000 claims description 17
- 239000003814 drug Substances 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 4
- 206010053398 Clonic convulsion Diseases 0.000 claims description 3
- 206010043994 Tonic convulsion Diseases 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 230000001256 tonic effect Effects 0.000 claims description 3
- 208000028326 generalized seizure Diseases 0.000 abstract description 4
- 150000001875 compounds Chemical class 0.000 abstract 1
- 241001465754 Metazoa Species 0.000 description 77
- CWRVKFFCRWGWCS-UHFFFAOYSA-N Pentrazole Chemical compound C1CCCCC2=NN=NN21 CWRVKFFCRWGWCS-UHFFFAOYSA-N 0.000 description 58
- 239000003981 vehicle Substances 0.000 description 46
- 230000000694 effects Effects 0.000 description 43
- 208000034308 Grand mal convulsion Diseases 0.000 description 16
- 206010009346 Clonus Diseases 0.000 description 13
- 210000003194 forelimb Anatomy 0.000 description 13
- 230000034994 death Effects 0.000 description 11
- 231100000517 death Toxicity 0.000 description 11
- 238000011161 development Methods 0.000 description 10
- 206010061334 Partial seizures Diseases 0.000 description 9
- 229930182555 Penicillin Natural products 0.000 description 9
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 9
- 238000010162 Tukey test Methods 0.000 description 9
- 229940049954 penicillin Drugs 0.000 description 9
- QCHFTSOMWOSFHM-WPRPVWTQSA-N (+)-Pilocarpine Chemical compound C1OC(=O)[C@@H](CC)[C@H]1CC1=CN=CN1C QCHFTSOMWOSFHM-WPRPVWTQSA-N 0.000 description 8
- 241000218236 Cannabis Species 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- QCHFTSOMWOSFHM-UHFFFAOYSA-N SJ000285536 Natural products C1OC(=O)C(CC)C1CC1=CN=CN1C QCHFTSOMWOSFHM-UHFFFAOYSA-N 0.000 description 8
- 230000001773 anti-convulsant effect Effects 0.000 description 8
- 230000002146 bilateral effect Effects 0.000 description 8
- 229960001416 pilocarpine Drugs 0.000 description 8
- 238000000540 analysis of variance Methods 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 6
- 238000001727 in vivo Methods 0.000 description 6
- 241000700159 Rattus Species 0.000 description 5
- 239000001961 anticonvulsive agent Substances 0.000 description 5
- 238000000876 binomial test Methods 0.000 description 5
- 230000007423 decrease Effects 0.000 description 5
- 238000001543 one-way ANOVA Methods 0.000 description 5
- 208000002033 Myoclonus Diseases 0.000 description 4
- 230000006399 behavior Effects 0.000 description 4
- 210000001320 hippocampus Anatomy 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007928 intraperitoneal injection Substances 0.000 description 4
- 210000003205 muscle Anatomy 0.000 description 4
- 230000001537 neural effect Effects 0.000 description 4
- 239000008389 polyethoxylated castor oil Substances 0.000 description 4
- 230000001144 postural effect Effects 0.000 description 4
- 230000000384 rearing effect Effects 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 241000282414 Homo sapiens Species 0.000 description 3
- 150000001200 N-acyl ethanolamides Chemical class 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 229960003965 antiepileptics Drugs 0.000 description 3
- 230000002566 clonic effect Effects 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000002621 endocannabinoid Substances 0.000 description 3
- 230000001747 exhibiting effect Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 230000036961 partial effect Effects 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 210000003478 temporal lobe Anatomy 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 206010008674 Cholinergic syndrome Diseases 0.000 description 2
- 241000700157 Rattus norvegicus Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 230000003556 anti-epileptic effect Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 230000001037 epileptic effect Effects 0.000 description 2
- 244000144993 groups of animals Species 0.000 description 2
- 230000003862 health status Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 210000003140 lateral ventricle Anatomy 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- LZCOQTDXKCNBEE-IKIFYQGPSA-N methscopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3[N+]([C@H](C2)[C@@H]2[C@H]3O2)(C)C)=CC=CC=C1 LZCOQTDXKCNBEE-IKIFYQGPSA-N 0.000 description 2
- 229960001383 methylscopolamine Drugs 0.000 description 2
- 230000003551 muscarinic effect Effects 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 229960002695 phenobarbital Drugs 0.000 description 2
- DDBREPKUVSBGFI-UHFFFAOYSA-N phenobarbital Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)NC1=O DDBREPKUVSBGFI-UHFFFAOYSA-N 0.000 description 2
- 239000000902 placebo Substances 0.000 description 2
- 229940068196 placebo Drugs 0.000 description 2
- 230000000216 proconvulsive effect Effects 0.000 description 2
- 238000011272 standard treatment Methods 0.000 description 2
- 238000000528 statistical test Methods 0.000 description 2
- 206010001497 Agitation Diseases 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010003628 Atonic seizures Diseases 0.000 description 1
- 102000018208 Cannabinoid Receptor Human genes 0.000 description 1
- 108050007331 Cannabinoid receptor Proteins 0.000 description 1
- 206010013643 Drop attacks Diseases 0.000 description 1
- 208000024658 Epilepsy syndrome Diseases 0.000 description 1
- 208000002877 Epileptic Syndromes Diseases 0.000 description 1
- 206010019196 Head injury Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 238000000585 Mann–Whitney U test Methods 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 229920005439 Perspex® Polymers 0.000 description 1
- CXOFVDLJLONNDW-UHFFFAOYSA-N Phenytoin Chemical compound N1C(=O)NC(=O)C1(C=1C=CC=CC=1)C1=CC=CC=C1 CXOFVDLJLONNDW-UHFFFAOYSA-N 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- 208000003443 Unconsciousness Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 208000028311 absence seizure Diseases 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 238000001949 anaesthesia Methods 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000002082 anti-convulsion Effects 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 230000002051 biphasic effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000003925 brain function Effects 0.000 description 1
- 230000002149 cannabinoid effect Effects 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 244000261228 chanvre indien Species 0.000 description 1
- 235000005607 chanvre indien Nutrition 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000028502 clonic seizure Diseases 0.000 description 1
- 230000007278 cognition impairment Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 244000096108 cunha Species 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000001787 epileptiform Effects 0.000 description 1
- 230000002964 excitative effect Effects 0.000 description 1
- 230000003492 excitotoxic effect Effects 0.000 description 1
- 231100000063 excitotoxicity Toxicity 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000000848 glutamatergic effect Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 230000008376 long-term health Effects 0.000 description 1
- 230000015654 memory Effects 0.000 description 1
- 230000004630 mental health Effects 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- 230000004118 muscle contraction Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000008587 neuronal excitability Effects 0.000 description 1
- 230000002853 ongoing effect Effects 0.000 description 1
- 229960005152 pentetrazol Drugs 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229960002036 phenytoin Drugs 0.000 description 1
- 239000004926 polymethyl methacrylate Substances 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 210000004129 prosencephalon Anatomy 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000013515 script Methods 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000000779 smoke Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000033504 synapse organization Effects 0.000 description 1
- 206010042772 syncope Diseases 0.000 description 1
- 201000008914 temporal lobe epilepsy Diseases 0.000 description 1
- 208000028500 tonic seizure Diseases 0.000 description 1
- 208000028325 tonic-clonic seizure Diseases 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A61P25/12—Antiepileptics; Anticonvulsants for grand-mal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
Definitions
- This invention relates to the use of one or a combination of phyto-cannabinoids in the treatment of epilepsy and more particularly to the use of tetrahydrocannabivarin (THCV) in the treatment of generalized seizure and / or cannabidiol (CBD) in
- Epilepsy is a chronic neurological disorder presenting a wide spectrum of diseases that affects approximately 50 million people worldwide (Sander, 2003).
- WO 2006/054057 makes reference to the potential use of THCV to treat epilepsy amongst a range of diseases.
- WO2009/007697 discloses formulations containing THCV and CBD.
- Cunha et al (1980) reported a study on 16 grand mal patients who were not doing well on conventional medication. They received their regular medication and either 200-300mg of cannabidiol or a placebo. Of the patients who received CBD, 3 showed complete improvement, 2 partial, 2 minor, while 1 remained unchanged. The only unwanted effect was mild sedation. Of the patients who received the placebo, 1 improved and 7 remained unchanged.
- Trembly et al (1990) reports an open trial with a single patient who was given 900-1200mg of cannabidiol a day for 10 months. This trial showed seizure frequency was markedly reduced in the patient.
- CBD tetrahydrocanibinol
- Neuronal activity is a prerequisite for proper brain function.
- disturbing the excitatory - inhibitory equilibrium of neuronal activity may induce epileptic seizures.
- epileptic seizures can be grouped into two basic categories: partial and generalised seizures. Partial seizures originate in specific brain regions and remain localised - most commonly the temporal lobes (containing the hippocampus), whereas generalised seizures appear in the entire forebrain as a secondary generalisation of a partial seizure (McCormick and Contreras, 2001 , Lutz, 2004).
- the league also categorized generalised seizures into numerous clinical seizure types, some examples of which are outlined below:
- Tonic-clonic seizures often known as "grand mal", are the most frequently encountered of the generalised seizures (Dreifuss et al., 1981 ).
- This generalised seizure type has two stages: tonic muscle contractions which then give way to a clonic stage of convulsive movements. The patient remains unconscious throughout the seizure and for a variable period of time afterwards.
- Atonic seizures are the result of sudden loss of muscle tone to either a specific muscle, muscle group or all muscles in the body (Dreifuss et al., 1981 ).
- cognitive deficits e.g. diminishing ability of neuronal circuits in the hippocampus to learn and store memories
- epilepsy also greatly affects the lifestyle of the sufferer - potentially living in fear of consequential injury (e.g. head injury) resulting from a grand ma/ seizure or the inability to perform daily tasks or the inability to drive a car unless having had a lengthy seizure-free period (Fisher et al., 2000).
- consequential injury e.g. head injury
- THCV tetrahydrocannabivarin
- CBD cannabidiol
- the medicament is to treat clonic and / or tonic seizures.
- the preferred daily dose of THCV is at least 1.5mg, more preferably at least 5mg through 10mg to15mg or more.
- the THCV is used in combination with at least a second
- CBD cannabinoid
- the CBD is preferably present in an amount which will provide a daily dose of at least 400mg, more preferably at least 600mg and as much as 800mg or more, but preferably less than 1200mg.
- the cannabinoids may be present as pure or isolated cannabinoids or in the form of plant extracts. Where a plant extract is used it is preferable that the THC content is less than 5% by weight of the total cannabinoids, more preferably less than 4% through 3%, 2% and 1 %. THC can be selectively removed from extracts using techniques such as chromatography.
- the invention also extends to using a phyto-cannabinoid in the manufacture of a medicament to treat a specific form of epilepsy.
- composition for use in treating generalised seizures and / or partial seizure comprising THCV and or CBD
- composition preferably takes the form of a plant extract containing one or more phytocannabinoids and one or more excipients.
- THCV and / or CBD for use in the manufacture of a medicament for use in the treatment of generalised seizures and / or partial seizure.
- Figure 1 shows latencies to initial and later seizure severities.
- the mean latencies to first myoclonic jerk (FMJ) and scores of 3.5 are shown ⁇ S. E. M. for vehicle or for low, medium or high doses of THCV BDS and 70mg/kg PTZ.
- n 8 - 10;
- Figure 2 shows seizure duration and time to death.
- n 3 - 10 dependent on proportions of animals that died within experimental groups.
- J vehicle group had no deaths and so no value is shown here;
- Figure 4 shows mortality rates. Mortality rates expressed as percentages for animals treated with vehicle or with low, medium or high doses of THCV BDS and
- Figure 5 shows latencies to initial and later seizure severities.
- the mean latencies to first myoclonic jerk (FMJ) and scores of 3.5 are shown ⁇ S. E. M. for vehicle or for low, medium or high doses of THCV BDS and 80mg/kg PTZ.
- n 7 - 10;
- Figure 7 shows median severity scores. Median severity scores for groups of animals treated with vehicle or with low, medium or high doses of THCV BDS prior to
- Figure 9 A-D show PTZ-induced seizure development and duration with pure THCV.
- D shows the mean duration of seizures (s) in animals that survived post-seizure. All values ⁇ S.E.M., * indicates significant difference from vehicle group (P ⁇ 0.05; Mann-Whitney U test);
- Figure 10 A-B show the effect of CBD on PTZ-induced seizures
- B % of vehicle- and CBD-dosed (1 , 10,100mg/kg CBD) animals that experienced tonic-clonic seizures as a result of IP injection of 80mg/kg PTZ. * indicates significant result (p ⁇ 0.01 );
- Figure 1 1 shows the lack of effect of THCV on the percentage mortality.
- Figure 12 shows the lack of effect of THCV on the mean maximum seizure severity. Significance was assessed by 1 -way ANOVA with Tukey's post-hoc test;
- Figure 13 A-D shows the percentage of animals in each group that reached specified seizure states when treated with THCV. Significant differences vs control were assessed using a binomial test. P ⁇ 0.05.
- Figure 14 shows the effect of CBD on the percentage mortality. Significance assessed by binomial test; * shows a significant increase in mortality (P ⁇ 0.05). Note that this effect only appeared at 10 mg/kg and was lost at 100 mg/kg, suggestive of a biphasic effect;
- Figure 15 shows the mean maximum seizure severity. Significance was assessed by 1 -way ANOVA with Tukey's post-hoc test; P>0.5 for all comparisons vs control;
- Figure 16 A-D describes the percentage of animals in each group that reached specified seizure states. Significant differences vs control were assessed using a binomial test. P ⁇ 0.05 ( * ); P ⁇ 0.001 ( *** );
- Figure 17 shows the effects of CBD upon mean tonic-clonic frequency.
- Figure 18 describes the percentage duration of time spent in a tonic-clonic state compared to the total duration of the seizure period. Significance was assessed using a one way ANOVA with Tukey's post-hoc test. P ⁇ 0.05 ( * );
- Figure 19 A-B describes the effects of CBD upon tonic-clonic seizures without postural control.
- A % of animals that experienced tonic-clonic seizures without postural control.
- B frequency with which animals displayed tonic-clonic seizures without postural control in the two hour recording period (or until death).
- A binomial statistical test;
- B one-way ANOVA followed by Tukey test. ** , *** and # indicate p ⁇ 0.01 , 0.001 and 0.1 respectively; and
- Figure 20 A-C describes the effect of CBD on penicillin-induced seizure severity and mortality.
- A Median severity of seizures (grey line), also shown is the 25th and 75th percentiles (black horizontal lines) and the maximum and minimum values (upward and downward error bars respectively).
- B Percentage of animals that remained seizure free throughout.
- C Percentage mortality.
- A one-way ANOVA followed by Tukey test.
- B&C binomial statistical test; * , *** and # indicate p ⁇ 0.05, 0.001 and 0.1.
- mice Male Wistar rats (P24-29; 75-1 10g) were used to assess the effects of the cannabinoids: THCV (BDS and pure) and CBD on the PTZ model of generalised seizures. Animals were habituated to the test environment, cages, injection protocol and handling prior to experimentation. Animals were housed in a room at 21 Q C on a 12 hour light: dark cycle (lights on 0900) in 50% humidity, with free access to food and water.
- THCV BDS and pure
- CBD cannabinoids
- a range of doses of PTZ (50-100mg/kg body weight) were used to determine the best dose for induction of seizures (see below). As a result, doses of 70 and
- IP intra-peritoneally
- cannabinoids low, medium or high dose
- cannabinoids vehicle 1 :1 :18 ethanol:Cremophor: 0.9%w/v NaCI solution
- Animals were then observed for 30 mins, after which time they received an IP injection of 70 or 80mg/kg PTZ.
- Negative vehicle controls were
- FMJ myoclonic jerk
- the THCV BDS comprised a whole extract of a chemovar in which THCV was the predominant cannabinoid. (i.e. it was the major cannabinoid present in the extract, 80% by weight of the total cannabinoid content).
- THC was the second most prevalent cannabinoid, and was present in significant amounts, (i.e. it comprised greater than 10% by weight of the total cannabinoid content, being present at about 16%), and there were a number of minor cannabinoids identified, each comprising less than 2% by weight of the total cannabinoid content as measured by HPLC analysis.
- the ratio of THCV to THC in this extract is about 5:1.
- the THCV content was 67.5% by weight of the extract and the THC content was 13.6% by weight of the extract, with the other identified cannabinoids in total comprising about 3% by weight of the extract, the remaining 16% comprising non- cannabinoids.
- THCV BDS The effect of THCV BDS on PTZ-induced seizures was first assessed against a PTZ dose of 70 mg/kg. As described below, this yielded a vehicle control group that did not typically experience severe seizure scores. Therefore THCV BDS was also screened against an 80mg/kg dose of PTZ. It was felt that the increased seizure severity experienced by vehicle control animals exposed to 80mg/kg PTZ was a more appropriate test of potential anti-convulsant activity.
- THCV BDS Three doses of THCV BDS were assessed against a concentration of PTZ known to induce moderate seizures in rats (70mg/kg; see pilot, above).
- the low, medium and high doses of THCV BDS used were 0.37, 3.70 and 37.04mg/kg, and yielded actual THCV doses of 0.25, 2.5 and 25mg/kg respectively. These doses were matched by THCV content to those being used for screening pure THCV against PTZ- induced seizures.
- THCV BDS did not have any significant effects on latency to first myoclonic jerk or on latency to attaining a severity score of 3.5 on the seizure severity scale (Fig 1 ). It should be noted that although values for both these variables were higher for animals treated with medium and high dose THCV BDS compared to control, this failed to reach significance (P>0.05). Similarly, no significant impact on duration of seizure was seen (Fig 2).
- THCV BDS did not have a significant effect on latencies to FMJ or a severity score of 3.5 (Fig 5). Similarly, no effect was observed on seizure durations (Fig 6).
- Low dose THCV BDS decreased both seizure severity (Fig 7) and mortality (Fig 8) in animals that received doses of 80mg/kg PTZ. Animals that received low THCV BDS had a lower median severity score (3.5 compared to 6) than vehicle controls. However, this difference was not significant (P>0.5). The low THCV BDS dose group also had a mortality rate half that of the vehicle control group (30% vs 60%).
- Groups treated with medium and high doses of THCV BDS had a lower seizure severity score of 4.75 (P>0.5 vs control), and a lower mortality rate of 50%, compared to 6 and 60% respectively.
- Table 3 below displays the values for median seizure severity in each experimental group.
- CBD was also screened in the PTZ model.
- IP intra-peritoneally
- IP intra-peritoneally
- THCV caused no significant changes in the percentage of animals showing unilateral forelimb clonus, bilateral forelimb clonus or tonic-clonic seizures at any dose. Interestingly, 0.25 mg/kg THCV caused a significant increase in the percentage of animals showing bilateral forelimb clonus with rearing and falling although this effect was not seen at any other dose.
- Figure 15 details that CBD had no effect upon the mean maximum severity of seizure reached per animal group.
- Figures ' ! 6 A-D detail the percentage of animals in each group that reached particular seizure states (unilateral forelimb clonus, bilateral forelimb clonus, bilateral forelimb clonus with rearing and falling and tonic-clonic).
- CBD caused significant decreases in the percentage of animals showing unilateral forelimb clonus at CBD doses >1 mg/kg, Interestingly, although no significant differences in the percentage of animals exhibiting bilateral forelimb clonus were found, the percentage of animals manifesting with bilateral forelimb clonus with rearing and falling were significantly reduces at all CBD doses >1 mg/kg. The percentage of animals exhibiting tonic-clonic seizures was significantly reduced at CBD doses of 1 mg/kg and 100 mg/kg but not 10 mg/kg (c.f. Figure 14).
- CBD effects of CBD upon tonic-clonic seizure events by examining the mean frequency of tonic-clonic events as is shown in Figure 17.
- CBD caused a significant reduction in mean tonic-clonic frequency at all doses tested.
- CBD effects upon the mean frequency of all other seizure scores were also assessed in the same way but no significant differences vs control were found (P>0.5 for all).
- CBD (1 , 10 and 100mg/kg) or CBD vehicle (1 :1 :18 ethanokCremophor: 0.9% W w // NaCI) was administered i.p. to adult male Wistar rats (>250g).
- animals had been surgically implanted with a cannula into the right lateral ventricle under anaesthesia.
- 150IU penicillin was infused into the right lateral ventricle in 1.5 ⁇ l saline solution over one minute and seizure behaviour video recorded for two hours.
- THCV pure
- CBD pure
- Such an extract may contain other cannabinoids and the non-cannabinoid components which result from extraction, by for example, carbon dioxide as disclosed in WO04/016277, which components may support an "entourage" effect in the endocannabinoid system.
- a rat / human conversion factor suggests a CBD daily dose of at least 600mg (and optionally between 400mg and 800mg) and for THCV at least 1.5mg (medium) to preferably at least 15mg (high).
- a phytocannabinoid extract is to be used, an extract with low or negligible levels of THC and therapeutically effective levels of THCV and / or CBD is desired.
- CONSROE P.F., WOOD, G.C. & BUCHSBAUM, H. (1975) Anticonvulsant Nature of Marihuana Smoking. J.American Medical Association 234 306-307
- Cannabis-psychosis pathway independent of other types of psychopathology HUIZINK, A. & VERHULST, F. C. (2005) Cannabis-psychosis pathway independent of other types of psychopathology. Schizophr Res, 79, 289-95.
- FISHER FISHER, R. S., VICKREY, B. G., GIBSON, P., HERMANN, B., PENOVICH, P., SCHERER, A. & WALKER, S. (2000) The impact of epilepsy from the patient's perspective I. Descriptions and subjective perceptions. Epilepsy Res, 41 , 39-51.
- Epilepsies Epilepsies. Epilepsia, 1 1 , 1 14-1 19.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
Claims
Priority Applications (26)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP10734541.5A EP2448637B2 (en) | 2009-07-03 | 2010-06-29 | Use of one or a combination of phyto-cannabinoids in the treatment of epilepsy |
RU2012103603/15A RU2563143C2 (en) | 2009-07-03 | 2010-06-29 | Application of one or combination of phytocannabinoids for treatment of epilepsy |
DK10734541.5T DK2448637T4 (en) | 2009-07-03 | 2010-06-29 | Use of a phytocannabinoid or a combination of phytocannabinoids in the treatment of epilepsy |
MX2012000257A MX2012000257A (en) | 2009-07-03 | 2010-06-29 | Use of one or a combination of phyto-cannabinoids in the treatment of epilepsy. |
BR112012000076-4A BR112012000076A2 (en) | 2009-07-03 | 2010-06-29 | USE OF CANABIDIOL IN THE PREPARATION OF A MEDICINE TO TREAT A PARTIAL CRISIS AND COMPOSITION UNDERSTANDING CANABIDIOL |
IN804DEN2012 IN2012DN00804A (en) | 2009-07-03 | 2010-06-29 | |
AU2010267775A AU2010267775C1 (en) | 2009-07-03 | 2010-06-29 | Use of one or a combination of phyto-cannabinoids in the treatment of epilepsy |
KR1020127003123A KR101727000B1 (en) | 2009-07-03 | 2010-06-29 | - Use of one or a combination of phytocannabinoids in the treatment of epilepsy |
CA2766082A CA2766082C (en) | 2009-07-03 | 2010-06-29 | Use of one or a combination of phyto-cannabinoids in the treatment of epilepsy |
CN2010800310652A CN102596322A (en) | 2009-07-03 | 2010-06-29 | Use of tetrahydrocannibivarin (THCV) and optionally cannabidiol (CBD) in the treatment of epilepsy |
ES10734541T ES2460623T5 (en) | 2009-07-03 | 2010-06-29 | Use of one or a combination of phyto-cannabinoids in the treatment of epilepsy |
UAA201201092A UA108852C2 (en) | 2009-07-03 | 2010-06-29 | Application of one or a combination of herbal cannabinoids for epilepsy treatment |
SG2011094042A SG176914A1 (en) | 2009-07-03 | 2010-06-29 | Use of one or a combination of phyto-cannabinoids in the treatment of epilepsy |
HRP20140398TT HRP20140398T4 (en) | 2009-07-03 | 2010-06-29 | Use of one or a combination of phyto-cannabinoids in the treatment of epilepsy |
US13/380,305 US9066920B2 (en) | 2009-07-03 | 2010-06-29 | Use of one or a combination of phyto-cannabinoids in the treatment of epilepsy |
PL10734541.5T PL2448637T5 (en) | 2009-07-03 | 2010-06-29 | Use of one or a combination of phyto-cannabinoids in the treatment of epilepsy |
NZ597704A NZ597704A (en) | 2009-07-03 | 2010-06-29 | Use of one or a combination of phyto-cannabinoids in the treatment of epilepsy |
EP20175934.7A EP3718603A1 (en) | 2009-07-03 | 2010-06-29 | Use of one or a combination of phytocannabinoids in the treatment of epilepsy |
JP2012516867A JP5904938B2 (en) | 2009-07-03 | 2010-06-29 | Use of one or a combination of phytocannabinoids in the treatment of epilepsy |
SI201030622T SI2448637T2 (en) | 2009-07-03 | 2010-06-29 | Use of one or a combination of phyto-cannabinoids in the treatment of epilepsy |
IL217280A IL217280B (en) | 2009-07-03 | 2011-12-29 | Cannabidiol and compositions containing same for use in treating partial seizures |
ZA2012/00373A ZA201200373B (en) | 2009-07-03 | 2012-01-17 | Use of one or a combination of phyto-cannabinoids in the treatment of epilepsy |
HK12105434.9A HK1164766A1 (en) | 2009-07-03 | 2012-06-05 | Use of one or a combination of phyto-cannabinoids in the treatment of epilepsy |
US14/579,061 US9522123B2 (en) | 2009-07-03 | 2014-12-22 | Use of one or a combination of phyto-cannabinoids in the treatment of epilepsy |
US15/346,844 US20170273913A1 (en) | 2009-07-03 | 2016-11-09 | Use of one or a combination of phyto-cannabinoids in the treatment of epilepsy |
US16/149,983 US20190247324A1 (en) | 2009-07-03 | 2018-10-02 | One or a Combination of Phyto-Cannabinoids in the Treatment of Epilepsy |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0911580A GB2471523A (en) | 2009-07-03 | 2009-07-03 | Use of tetrahydrocannibivarin (THCV) and optionally cannabidiol (CBD) in the treatment of epilepsy |
GB0911580.9 | 2009-07-03 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/380,305 A-371-Of-International US9066920B2 (en) | 2009-07-03 | 2010-06-29 | Use of one or a combination of phyto-cannabinoids in the treatment of epilepsy |
US14/579,061 Continuation US9522123B2 (en) | 2009-07-03 | 2014-12-22 | Use of one or a combination of phyto-cannabinoids in the treatment of epilepsy |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2011001169A1 true WO2011001169A1 (en) | 2011-01-06 |
Family
ID=41008705
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB2010/051066 WO2011001169A1 (en) | 2009-07-03 | 2010-06-29 | Use of one or a combination of phyto-cannabinoids in the treatment of epilepsy |
Country Status (29)
Country | Link |
---|---|
US (4) | US9066920B2 (en) |
EP (3) | EP2448637B2 (en) |
JP (2) | JP5904938B2 (en) |
KR (1) | KR101727000B1 (en) |
CN (2) | CN102596322A (en) |
AR (1) | AR077448A1 (en) |
AU (1) | AU2010267775C1 (en) |
BR (1) | BR112012000076A2 (en) |
CA (2) | CA3040410C (en) |
CY (1) | CY1115338T1 (en) |
DK (1) | DK2448637T4 (en) |
ES (1) | ES2460623T5 (en) |
GB (3) | GB2471523A (en) |
HK (1) | HK1164766A1 (en) |
HR (1) | HRP20140398T4 (en) |
IL (1) | IL217280B (en) |
IN (1) | IN2012DN00804A (en) |
MX (1) | MX2012000257A (en) |
MY (1) | MY156759A (en) |
NZ (2) | NZ620838A (en) |
PL (1) | PL2448637T5 (en) |
PT (1) | PT2448637E (en) |
RU (1) | RU2563143C2 (en) |
SG (1) | SG176914A1 (en) |
SI (1) | SI2448637T2 (en) |
TW (1) | TWI461191B (en) |
UA (1) | UA108852C2 (en) |
WO (1) | WO2011001169A1 (en) |
ZA (1) | ZA201200373B (en) |
Cited By (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2552430A1 (en) * | 2010-03-30 | 2013-02-06 | GW Pharma Limited | Use of the phytocannabinoid cannabidivarin (cbdv) in the treatment of epilepsy |
WO2013045891A1 (en) * | 2011-09-29 | 2013-04-04 | Gw Pharma Limited | A pharmaceutical composition comprising the phytocannabinoids cannabidivarin (cbdv) and cannabidiol (cbd) |
US9066920B2 (en) | 2009-07-03 | 2015-06-30 | Gw Pharma Limited | Use of one or a combination of phyto-cannabinoids in the treatment of epilepsy |
WO2015193667A1 (en) * | 2014-06-17 | 2015-12-23 | Gw Pharma Limited | Use of cannabinoids in the treatment of epilepsy |
US10092525B2 (en) | 2014-10-14 | 2018-10-09 | Gw Pharma Limited | Use of cannabinoids in the treatment of epilepsy |
US10143706B2 (en) | 2016-06-29 | 2018-12-04 | Cannscience Innovations, Inc. | Decarboxylated cannabis resins, uses thereof and methods of making same |
US10583096B2 (en) | 2016-03-31 | 2020-03-10 | GW Research Limited | Use of cannabinoids in the treatment of epilepsy |
US10709671B2 (en) | 2015-06-17 | 2020-07-14 | GW Research Limited | Use of cannabinoids in the treatment of epilepsy |
US10765643B2 (en) | 2014-10-14 | 2020-09-08 | GW Research Limited | Use of cannabidiol in the treatment of epilepsy |
WO2020225540A1 (en) | 2019-05-03 | 2020-11-12 | GW Research Limited | Use of cannabidiol in the treatment of tuberous sclerosis complex |
US10918608B2 (en) | 2014-10-14 | 2021-02-16 | GW Research Limited | Use of cannabidiol in the treatment of epilepsy |
US11065227B2 (en) | 2016-08-25 | 2021-07-20 | GW Research Limited | Use of cannabinoids in the treatment of multiple myeloma |
US11147776B2 (en) | 2014-06-27 | 2021-10-19 | GW Research Limited | 7-OH-cannabidiol (7-OH-CBD) and/or 7-OH-cannabidivarin (7-OH-CBDV) for use in the treatment of epilepsy |
US11147783B2 (en) | 2015-08-10 | 2021-10-19 | GW Research Limited | Use of cannabinoids in the treatment of epilepsy |
US11160757B1 (en) | 2020-10-12 | 2021-11-02 | GW Research Limited | pH dependent release coated microparticle cannabinoid formulations |
US11160795B2 (en) | 2020-02-27 | 2021-11-02 | GW Research Limited | Methods of treating tuberous sclerosis complex with cannabidiol and everolimus |
US11229612B2 (en) | 2016-07-01 | 2022-01-25 | GW Research Limited | Parenteral formulations |
WO2022017936A1 (en) * | 2020-07-20 | 2022-01-27 | GW Research Limited | Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to structural abnormalities of the brain |
WO2022017909A1 (en) * | 2020-07-20 | 2022-01-27 | GW Research Limited | Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to structural abnormalities of the brain |
US11291631B2 (en) | 2016-07-01 | 2022-04-05 | GW Research Limited | Oral cannabinoid formulations |
US11351152B2 (en) | 2016-06-15 | 2022-06-07 | India Globalization Capital, Inc. | Method and composition for treating seizure disorders |
US11426362B2 (en) | 2017-02-17 | 2022-08-30 | GW Research Limited | Oral cannabinoid formulations |
WO2022180379A1 (en) | 2021-02-25 | 2022-09-01 | GW Research Limited | Use of cannabidiol and clobazam in the treatment of childhood-onset epilepsy syndromes |
US11679087B2 (en) | 2016-12-16 | 2023-06-20 | GW Research Limited | Use of cannabinoids in the treatment of Angelman syndrome |
US11806319B2 (en) | 2018-01-03 | 2023-11-07 | GW Research Limited | Pharmaceutical composition comprising a cannabinoid |
US11865102B2 (en) | 2018-04-27 | 2024-01-09 | GW Research Limited | Cannabidiol preparations and its uses |
US11911361B2 (en) | 2014-05-29 | 2024-02-27 | Radius Pharmaceuticals, Inc. | Stable cannabinoid formulations |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2377218A (en) * | 2001-05-04 | 2003-01-08 | Gw Pharmaceuticals Ltd | Process and apparatus for extraction of active substances and enriched extracts from natural products |
AU2005305675B2 (en) * | 2004-11-16 | 2012-12-13 | Gw Pharma Limited | New use for cannabinoid |
GB0425248D0 (en) | 2004-11-16 | 2004-12-15 | Gw Pharma Ltd | New use for cannabinoid |
GB2479153B (en) * | 2010-03-30 | 2014-03-19 | Gw Pharma Ltd | The phytocannabinoid cannabidivarin (CBDV) for use in the treatment of epilepsy |
GB2487712B (en) * | 2011-01-04 | 2015-10-28 | Otsuka Pharma Co Ltd | Use of the phytocannabinoid cannabidiol (CBD) in combination with a standard anti-epileptic drug (SAED) in the treatment of epilepsy |
US10117891B2 (en) | 2014-09-16 | 2018-11-06 | India Globalization Capital, Inc. | Cannabinoid composition for treating pain |
US10751300B2 (en) | 2015-01-25 | 2020-08-25 | India Globalization Capital, Inc. | Composition and method for treating seizure disorders |
US10238745B2 (en) | 2015-01-31 | 2019-03-26 | Constance Therapeutics, Inc. | Cannabinoid composition and products including α-tocopherol |
AU2016211314A1 (en) | 2015-01-31 | 2017-08-17 | Constance Therapeutics, Inc. | Methods for preparation of cannabis oil extracts and compositions |
CA2981285A1 (en) * | 2015-04-01 | 2016-10-06 | India Globalization Capital, Inc. | Composition and method for treating seizure disorders |
WO2016176279A1 (en) * | 2015-04-28 | 2016-11-03 | The Regents Of The University Of California | Uses of cannabidiol for treatment of infantile spasms |
US9585867B2 (en) | 2015-08-06 | 2017-03-07 | Charles Everett Ankner | Cannabinod formulation for the sedation of a human or animal |
WO2017027651A1 (en) | 2015-08-12 | 2017-02-16 | India Globalization Capital, Inc. | Method and composition for treating cachexia and eating disorders |
IL299047A (en) | 2015-11-24 | 2023-02-01 | Constance Therapeutics Inc | Cannabis oil compositions and methods for preparation thereof |
US10499584B2 (en) | 2016-05-27 | 2019-12-10 | New West Genetics | Industrial hemp Cannabis cultivars and seeds with stable cannabinoid profiles |
CN108236608B (en) * | 2016-12-27 | 2020-05-08 | 汉义生物科技(北京)有限公司 | Pharmaceutical composition of cannabidiol and vigabatrin and application thereof |
CN108245499B (en) * | 2016-12-29 | 2020-11-20 | 汉义生物科技(北京)有限公司 | Composition of cannabidiol and double-chain fatty acid antiepileptic medicine and application thereof |
CN108245510B (en) * | 2016-12-29 | 2020-11-20 | 汉义生物科技(北京)有限公司 | Composition of cannabidiol and acryloyl urea antiepileptic drugs and application thereof |
CN108245517B (en) * | 2016-12-29 | 2020-05-08 | 汉义生物科技(北京)有限公司 | Pharmaceutical composition of cannabidiol and lamotrigine and application thereof |
CN108785298A (en) * | 2017-04-27 | 2018-11-13 | 汉义生物科技(北京)有限公司 | A kind of pharmaceutical composition, preparation method and the usage for treating epilepsy |
US20180352848A1 (en) * | 2017-06-07 | 2018-12-13 | NC3 Systems | Smokable cannabis-based product with reduced psychoactive effects |
CN110101804A (en) * | 2019-05-30 | 2019-08-09 | 厦门梓素生物科技有限公司 | A kind of epilepsy drugs combination of the extract containing cannabidiol and preparation method thereof |
WO2021055493A1 (en) * | 2019-09-17 | 2021-03-25 | Zynerba Pharmaceuticals, Inc. | Treatment of syngap1 encephalopathy |
EP3912485A1 (en) | 2020-05-18 | 2021-11-24 | Del-Vis Sp. z o.o. | Cigarette product and a method for manufacturing the product |
MX2023001129A (en) | 2020-07-28 | 2023-03-27 | Impello Biosciences Inc | Methods and compositions for altering secondary metabolites in plants. |
US11337934B1 (en) | 2021-04-08 | 2022-05-24 | Lanny Leo Johnson | Compositions including a cannabinoid and protocatechuic acid |
WO2023009817A2 (en) | 2021-07-29 | 2023-02-02 | Emory University | Phosphate prodrugs of cannabinoids |
WO2023200906A1 (en) * | 2022-04-12 | 2023-10-19 | Shackelford Pharma Inc. | Treatment of seizure disorders |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002064109A2 (en) | 2001-02-14 | 2002-08-22 | Gw Pharma Limited | Mucoadhesive pharmaceutical formulations |
WO2004016277A2 (en) | 2002-08-14 | 2004-02-26 | Gw Pharma Limited | Extraction of pharmaceutically active cannabinoids from plant materials |
WO2004016246A1 (en) * | 2002-08-14 | 2004-02-26 | Gw Pharma Limited | Cannabinoid liquid formulations for mucosal amdinistration |
US20060039959A1 (en) * | 2002-06-14 | 2006-02-23 | Werner Wessling | Film-Shaped Mucoadhesive Administration Forms For Administering Cannabis Agents |
WO2006054057A2 (en) | 2004-11-16 | 2006-05-26 | Gw Pharma Limited | New use for cannabinoid |
WO2009007697A1 (en) | 2007-07-06 | 2009-01-15 | Gw Pharma Limited | New pharmaceutical formulation comprising cannabidiol and tetrahydrocannabidivarin |
Family Cites Families (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6949582B1 (en) | 1999-05-27 | 2005-09-27 | Wallace Walter H | Method of relieving analgesia and reducing inflamation using a cannabinoid delivery topical liniment |
DE10051427C1 (en) * | 2000-10-17 | 2002-06-13 | Adam Mueller | Process for the production of an extract containing tetrahydrocannabinol and cannabidiol from cannabis plant material and cannabis extracts |
GB2381450B (en) * | 2001-10-31 | 2006-05-31 | Gw Pharma Ltd | Compositions for administration of natural or synthetic cannabinoids by vaporisation |
GB0202385D0 (en) | 2002-02-01 | 2002-03-20 | Gw Pharma Ltd | Compositions for the treatment of nausea,vomiting,emesis,motion sicknes or like conditions |
ITPD20020138A1 (en) | 2002-05-24 | 2003-11-24 | Matteo Bevilacqua | COMPOSITION OF TERPENIC-BASED SUBSTANCES, METHOD OF PREPARATION AND METHOD OF DISPERSION IN THE ENVIRONMENT OF THE SAME. |
GB0425248D0 (en) * | 2004-11-16 | 2004-12-15 | Gw Pharma Ltd | New use for cannabinoid |
TWI366460B (en) | 2005-06-16 | 2012-06-21 | Euro Celtique Sa | Cannabinoid active pharmaceutical ingredient for improved dosage forms |
GB2434312B (en) | 2006-01-18 | 2011-06-29 | Gw Pharma Ltd | Cannabinoid-containing plant extracts as neuroprotective agents |
WO2007142957A2 (en) | 2006-05-30 | 2007-12-13 | Air Systems | Gear drive damper |
GB2438682A (en) | 2006-06-01 | 2007-12-05 | Gw Pharma Ltd | New use for cannabinoids |
GB2439393B (en) * | 2006-06-23 | 2011-05-11 | Gw Pharma Ltd | Cannabinoids for use in the treatment of neuropathic pain |
GB2449691A (en) | 2007-05-31 | 2008-12-03 | Gw Pharma Ltd | A reference plant lacking medicinal active compound expression |
GB2456183A (en) | 2008-01-04 | 2009-07-08 | Gw Pharma Ltd | Anti-psychotic composition comprising cannabinoids and anti-psychotic medicament |
GB2459637B (en) | 2008-01-21 | 2012-06-06 | Gw Pharma Ltd | New use for cannabinoids |
PT2280687T (en) | 2008-03-26 | 2019-06-04 | Stichting Sanammad | Chewing gum compositions comprising cannabinoids |
GB2478074B (en) | 2008-06-04 | 2012-12-26 | Gw Pharma Ltd | Anti-tumoural effects of cannabinoid combinations |
GB2478072B (en) | 2008-06-04 | 2012-12-26 | Gw Pharma Ltd | Anti-tumoural effects of cannabinoid combinations |
GB2471523A (en) | 2009-07-03 | 2011-01-05 | Gw Pharma Ltd | Use of tetrahydrocannibivarin (THCV) and optionally cannabidiol (CBD) in the treatment of epilepsy |
GB2478595B (en) | 2010-03-12 | 2018-04-04 | Gw Pharma Ltd | Phytocannabinoids in the treatment of glioma |
GB2479153B (en) | 2010-03-30 | 2014-03-19 | Gw Pharma Ltd | The phytocannabinoid cannabidivarin (CBDV) for use in the treatment of epilepsy |
TWI583374B (en) | 2010-03-30 | 2017-05-21 | Gw伐瑪有限公司 | Use of the phytocannabinoid cannabidivarin (cbdv) in the treatment of epilepsy |
US8895537B2 (en) | 2010-10-29 | 2014-11-25 | Infirst Healthcare Ltd. | Compositions and methods for treating cardiovascular diseases |
GB2487712B (en) | 2011-01-04 | 2015-10-28 | Otsuka Pharma Co Ltd | Use of the phytocannabinoid cannabidiol (CBD) in combination with a standard anti-epileptic drug (SAED) in the treatment of epilepsy |
GB201111261D0 (en) | 2011-07-01 | 2011-08-17 | Gw Pharma Ltd | Cannabinoids for use in the treatment of neuro-degenerative diseases or disorders |
RU2639120C2 (en) | 2011-08-26 | 2017-12-19 | Биал-Портела Энд Ка, С.А. | Treatment using eslicarbazepine acetate or eslicarbazepine |
GB2514054A (en) | 2011-09-29 | 2014-11-12 | Gw Pharma Ltd | A pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD) |
GB2496687A (en) | 2011-11-21 | 2013-05-22 | Gw Pharma Ltd | Tetrahydrocannabivarin (THCV) in the protection of pancreatic islet cells |
US20150181924A1 (en) | 2013-10-31 | 2015-07-02 | Michael R. Llamas | Cannabidiol liquid composition for smoking |
US10052339B2 (en) | 2014-03-21 | 2018-08-21 | Bodybio Inc. | Methods and compositions for treating symptoms of diseases related to imbalance of essential fatty acids |
CA2950424C (en) | 2014-05-29 | 2023-03-14 | Insys Pharma, Inc. | Stable cannabinoid formulations |
GB2530001B (en) | 2014-06-17 | 2019-01-16 | Gw Pharma Ltd | Use of cannabidiol in the reduction of convulsive seizure frequency in treatment-resistant epilepsy |
GB2531282A (en) | 2014-10-14 | 2016-04-20 | Gw Pharma Ltd | Use of cannabinoids in the treatment of epilepsy |
GB2531281A (en) | 2014-10-14 | 2016-04-20 | Gw Pharma Ltd | Use of cannabidiol in the treatment of intractable epilepsy |
-
2009
- 2009-07-03 GB GB0911580A patent/GB2471523A/en not_active Withdrawn
-
2010
- 2010-06-29 EP EP10734541.5A patent/EP2448637B2/en active Active
- 2010-06-29 WO PCT/GB2010/051066 patent/WO2011001169A1/en active Application Filing
- 2010-06-29 HR HRP20140398TT patent/HRP20140398T4/en unknown
- 2010-06-29 CA CA3040410A patent/CA3040410C/en active Active
- 2010-06-29 GB GB1010897.5A patent/GB2471565B/en active Active
- 2010-06-29 PL PL10734541.5T patent/PL2448637T5/en unknown
- 2010-06-29 SG SG2011094042A patent/SG176914A1/en unknown
- 2010-06-29 IN IN804DEN2012 patent/IN2012DN00804A/en unknown
- 2010-06-29 NZ NZ620838A patent/NZ620838A/en unknown
- 2010-06-29 BR BR112012000076-4A patent/BR112012000076A2/en not_active Application Discontinuation
- 2010-06-29 MX MX2012000257A patent/MX2012000257A/en active IP Right Grant
- 2010-06-29 US US13/380,305 patent/US9066920B2/en active Active
- 2010-06-29 GB GB1121919.3A patent/GB2485291B/en not_active Expired - Fee Related
- 2010-06-29 KR KR1020127003123A patent/KR101727000B1/en active IP Right Grant
- 2010-06-29 MY MYPI2011006198A patent/MY156759A/en unknown
- 2010-06-29 UA UAA201201092A patent/UA108852C2/en unknown
- 2010-06-29 RU RU2012103603/15A patent/RU2563143C2/en active
- 2010-06-29 SI SI201030622T patent/SI2448637T2/en unknown
- 2010-06-29 CA CA2766082A patent/CA2766082C/en active Active
- 2010-06-29 CN CN2010800310652A patent/CN102596322A/en active Pending
- 2010-06-29 EP EP14153495.8A patent/EP2727626A1/en not_active Withdrawn
- 2010-06-29 ES ES10734541T patent/ES2460623T5/en active Active
- 2010-06-29 NZ NZ597704A patent/NZ597704A/en unknown
- 2010-06-29 PT PT107345415T patent/PT2448637E/en unknown
- 2010-06-29 EP EP20175934.7A patent/EP3718603A1/en active Pending
- 2010-06-29 CN CN201610808754.9A patent/CN106236744A/en active Pending
- 2010-06-29 DK DK10734541.5T patent/DK2448637T4/en active
- 2010-06-29 AU AU2010267775A patent/AU2010267775C1/en active Active
- 2010-06-29 JP JP2012516867A patent/JP5904938B2/en active Active
- 2010-07-02 TW TW099121811A patent/TWI461191B/en active
- 2010-07-02 AR ARP100102377A patent/AR077448A1/en unknown
-
2011
- 2011-12-29 IL IL217280A patent/IL217280B/en active IP Right Grant
-
2012
- 2012-01-17 ZA ZA2012/00373A patent/ZA201200373B/en unknown
- 2012-06-05 HK HK12105434.9A patent/HK1164766A1/en unknown
-
2014
- 2014-05-12 CY CY20141100335T patent/CY1115338T1/en unknown
- 2014-12-22 US US14/579,061 patent/US9522123B2/en active Active
-
2016
- 2016-03-15 JP JP2016050485A patent/JP2016166205A/en active Pending
- 2016-11-09 US US15/346,844 patent/US20170273913A1/en not_active Abandoned
-
2018
- 2018-10-02 US US16/149,983 patent/US20190247324A1/en not_active Abandoned
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002064109A2 (en) | 2001-02-14 | 2002-08-22 | Gw Pharma Limited | Mucoadhesive pharmaceutical formulations |
US20060039959A1 (en) * | 2002-06-14 | 2006-02-23 | Werner Wessling | Film-Shaped Mucoadhesive Administration Forms For Administering Cannabis Agents |
WO2004016277A2 (en) | 2002-08-14 | 2004-02-26 | Gw Pharma Limited | Extraction of pharmaceutically active cannabinoids from plant materials |
WO2004016246A1 (en) * | 2002-08-14 | 2004-02-26 | Gw Pharma Limited | Cannabinoid liquid formulations for mucosal amdinistration |
WO2006054057A2 (en) | 2004-11-16 | 2006-05-26 | Gw Pharma Limited | New use for cannabinoid |
WO2009007697A1 (en) | 2007-07-06 | 2009-01-15 | Gw Pharma Limited | New pharmaceutical formulation comprising cannabidiol and tetrahydrocannabidivarin |
Non-Patent Citations (30)
Title |
---|
"Marijuana and medicine: Assessing the science base", 1999, NATIONAL ACADEMY PRESS |
ALGER, B. E.: "Not too excited? Thank your endocannabinoids", NEURON, vol. 51, 2006, pages 393 - 5 |
AMES FR.: "Anticonvulsant effect of cannabidiol", SOUTH AFRICAN MEDICAL JOURNAL, vol. 69, 1986, pages 14 |
AVOLI, M.; LOUVEL, J.; PUMAIN, R.; KOHLING, R.: "Cellular and molecular mechanisms of epilepsy in the human brain", PROG NEUROBIOL, 2005 |
BOSTANCI, M. O.; BAGIRICI, F.: "The effects of octanol on penicillin induced epileptiform activity in rats: an in vivo study", EPILEPSY RES, vol. 71, 2006, pages 188 - 94 |
BRUST, J. C.; NG, S. K.; HAUSER, A. W.; SUSSER, M.: "Marijuana use and the risk of new onset seizures", TRANS AM CLIN CLIMATOL ASSOC, vol. 103, 1992, pages 176 - 81 |
CONSROE P ET AL: "Effects of cannabidiol on behavioral seizures caused by convulsant drugs or current in mice", EUROPEAN JOURNAL OF PHARMACOLOGY, vol. 83, no. 3-4, 1982, NL, pages 293 - 298, XP002609659, ISSN: 0014-2999 * |
CONSROE, P.F.; WOOD, G.C.; BUCHSBAUM, H.: "Anticonvulsant Nature of Marihuana Smoking", J.AMERICAN MEDICAL ASSOCIATION, vol. 234, 1975, pages 306 - 307 |
CUNHA J M ET AL: "Chronic administration of cannabidiol to healthy volunteers and epileptic patients", PHARMACOLOGY, S. KARGER AG, CH, vol. 21, no. 3, 1 January 1980 (1980-01-01), pages 175 - 185, XP009139434, ISSN: 0031-7012 * |
CUNHA, J. M.; CARLINI, E. A.; PEREIRA, A. E.; RAMOS, O. L.; PIMENTEL, C.; GAGLIARDI, R.; SANVITO, W. L.; LANDER, N.; MECHOULAM, R.: "Chronic administration of cannabidiol to healthy volunteers and epileptic patients", PHARMACOLOGY, vol. 21, 1980, pages 175 - 85 |
DAVIS, J P.; RAMSEY, H.H.: "Antiepileptic Action of Marijuana-active Substances", FEDERATION PROCEEDINGS, vol. 8, 1949, pages 284 - 285 |
DREIFUSS, F. E.; BANCAUD, J.; HENRIKSEN, O.; RUBIO-DONNADIEU, F.PENRY, J. K.; SEINO, M.: "Proposal for revised clinical and electroencephalographic classification of epileptic seizures", EPILEPSIA, vol. 22, 1981, pages 489 - 501 |
FERDINAND, R. F.; VAN DER ENDE, J.; BONGERS, I.; SELTEN, J. P.; HUIZINK, A.; VERHULST, F. C.: "Cannabis--psychosis pathway independent of other types of psychopathology", SCHIZOPHR RES, vol. 79, 2005, pages 289 - 95 |
FISHER, R. S.; VICKREY, B. G.; GIBSON, P.; HERMANN, B.; PENOVICH, P.; SCHERER, A.; WALKER, S.: "The impact of epilepsy from the patient's perspective . Descriptions and subjective perceptions", EPILEPSY RES, vol. 41, 2000, pages 39 - 51 |
GASTAUT, H.: "Clinical and Electroencephalographical Classification of Epileptic Seizures", EPILEPSIA, vol. 11, 1970, pages 102 - 112 |
HILL ANDREW J ET AL: "Delta 9-Tetrahydrocannabivarin suppresses in vitro epileptiform and in vivo seizure activity in adult rats", EPILEPSIA, vol. 51, no. 8, August 2010 (2010-08-01), pages 1522 - 1532, XP002609658, ISSN: 0013-9580, DOI: 10.1111/j.1528-1167.2010.02523.x * |
LUTZ, B.: "On-demand activation of the endocannabinoid system in the control of neuronal excitability and epileptiform seizures", BIOCHEM PHARMACOL, vol. 68, 2004, pages 1691 - 8 |
MACKIE, K.: "Cannabinoid receptors as therapeutic targets", ANNU REV PHARMACOL TOXICOL, vol. 46, 2006, pages 101 - 22 |
MCCORMICK, D. A.; CONTRERAS, D.: "On the cellular and network bases of epileptic seizures", ANNU REV PHYSIOL, vol. 63, 2001, pages 815 - 46 |
MERLIS, J. K.: "Proposal for an International Classification of the Epilepsies", EPILEPSIA, vol. 11, 1970, pages 114 - 119 |
NG ET AL.: "Illicit drug use and the risk of new-onset seizures", AMERICAN JOURNAL OF EPIDEMIOLOGY, vol. 132, 1990, pages 47 - 57 |
OBAY, B. D.; TASDEMIR, E.; TUMER, C.; BILGIN, H. M.; SERMET, A.: "Antiepileptic effects of ghrelin on pentylenetetrazole-induced seizures in rats", PEPTIDES, vol. 28, 2007, pages 1214 - 9 |
PEREIRA, M. B.; FREITAS, R. L.; ASSIS, M. A.; SILVA, R. F.; FONTELES, M. M.; FREITAS, R. M.; TAKAHASHI, R. N.: "Study pharmacologic of the GABAergic and glutamatergic drugs on seizures and status epilepticus induced by pilocarpine in adult Wistar rats", NEUROSCI LETT, vol. 419, 2007, pages 253 - 7 |
POHL; MARES, EPILEPSY RES, vol. 1, 1987, pages 302 - 305 |
RAUCA, C.; WISWEDEL, I.; ZERBE, R.; KEILHOFF, G.; KRUG, M.: "The role of superoxide dismutase and alpha-tocopherol in the development of seizures and kindling induced by pentylenetetrazol - influence of the radical scavenger alpha- phenyl-N-tert-butyl nitrone", BRAIN RES, vol. 1009, 2004, pages 203 - 12 |
SANDER, J. W.: "The epidemiology of epilepsy revisited", CURR OPIN NEUROL, vol. 16, 2003, pages 165 - 70 |
SWANN, J. W.: "The effects of seizures on the connectivity and circuitry of the developing brain", MENT RETARD DEV DISABIL RES REV, vol. 10, 2004, pages 96 - 100 |
TREMBLY B.; SHERMAN M.: "Marijuana '90 International Conference on Cannabis and Cannabinoids", 8 July 1990, article "Double-blind clinical study of cannabidiol as a secondary anticonvulsant" |
USAMI NORIYUKI ET AL: "Synthesis and pharmacological evaluation in mice of halogenated cannabidiol derivatives", CHEMICAL AND PHARMACEUTICAL BULLETIN, vol. 47, no. 11, November 1999 (1999-11-01), (TOKYO), pages 1641 - 1645, XP002609660, ISSN: 0009-2363 * |
WINGERCHUK, D.: "Cannabis for medical purposes: cultivating science, weeding out the fiction", LANCET, vol. 364, 2004, pages 315 - 6 |
Cited By (76)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9066920B2 (en) | 2009-07-03 | 2015-06-30 | Gw Pharma Limited | Use of one or a combination of phyto-cannabinoids in the treatment of epilepsy |
US9522123B2 (en) | 2009-07-03 | 2016-12-20 | Gw Pharma Limited | Use of one or a combination of phyto-cannabinoids in the treatment of epilepsy |
US12023305B2 (en) | 2010-03-30 | 2024-07-02 | Gw Pharma Limited | Use of the phytocannabinoid cannabidivarin (CBDV) in the treatment of epilepsy |
EP3763361A1 (en) * | 2010-03-30 | 2021-01-13 | GW Pharma Limited | Cannabidivarin (cbdv) for use in the treatment of epilepsy |
EP2552430A1 (en) * | 2010-03-30 | 2013-02-06 | GW Pharma Limited | Use of the phytocannabinoid cannabidivarin (cbdv) in the treatment of epilepsy |
US9125859B2 (en) | 2010-03-30 | 2015-09-08 | Gw Pharma Limited | Use of the phytocannabinoid cannabidivarin (CBDV) in the treatment of epilepsy |
US10799467B2 (en) | 2010-03-30 | 2020-10-13 | Gw Pharma Limited | Use of the phytocannabinoid cannabidivarin (CBDV) in the treatment of epilepsy |
EP3763361B1 (en) * | 2010-03-30 | 2024-06-26 | GW Pharma Limited | Cannabidivarin (cbdv) for use in the treatment of epilepsy |
CN108354914A (en) * | 2011-09-29 | 2018-08-03 | Gw药品有限公司 | Include the pharmaceutical composition of plant cannabinoids cannabidivarin (CBDV) and cannabidiol (CBD) |
WO2013045891A1 (en) * | 2011-09-29 | 2013-04-04 | Gw Pharma Limited | A pharmaceutical composition comprising the phytocannabinoids cannabidivarin (cbdv) and cannabidiol (cbd) |
CN103826621A (en) * | 2011-09-29 | 2014-05-28 | Gw药品有限公司 | A pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD) |
EP3821885A1 (en) * | 2011-09-29 | 2021-05-19 | GW Pharma Limited | A pharmaceutical composition comprising the phytocannabinoids cannabidivarin (cbdv) and cannabidiol (cbd) |
US10729665B2 (en) | 2011-09-29 | 2020-08-04 | Gw Pharma Limited | Pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD) |
US11318109B2 (en) | 2011-09-29 | 2022-05-03 | Gw Pharma Limited | Pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD) |
EA029697B1 (en) * | 2011-09-29 | 2018-05-31 | ДжиДаблЮ ФАРМА ЛИМИТЕД | Pharmaceutical composition comprising the phytocannabinoids cannabidivarin (cbdv) and cannabidiol (cbd) |
IL280294A (en) * | 2011-09-29 | 2021-03-01 | Gw Pharma Ltd | A pharmaceutical composition comprising the phytocannabinoids cannabidivarin (cbdv) and cannabidiol (cbd) |
TWI577373B (en) * | 2011-09-29 | 2017-04-11 | Gw伐瑪有限公司 | A pharmaceutical composition comprising the phytocannabinoids cannabidivarin (cbdv) and cannabidiol (cbd) |
IL280294B2 (en) * | 2011-09-29 | 2023-05-01 | Gw Pharma Ltd | A pharmaceutical composition comprising the phytocannabinoids cannabidivarin (cbdv) and cannabidiol (cbd) |
US11911361B2 (en) | 2014-05-29 | 2024-02-27 | Radius Pharmaceuticals, Inc. | Stable cannabinoid formulations |
US11311498B2 (en) | 2014-06-17 | 2022-04-26 | GW Research Limited | Use of cannabinoids in the treatment of epilepsy |
US9956184B2 (en) | 2014-06-17 | 2018-05-01 | Gw Pharma Limited | Use of cannabinoids in the treatment of epilepsy |
US9949936B2 (en) | 2014-06-17 | 2018-04-24 | Gw Pharma Limited | Use of cannabinoids in the treatment of epilepsy |
US11766411B2 (en) | 2014-06-17 | 2023-09-26 | GW Research Limited | Use of cannabinoids in the treatment of epilepsy |
US11701330B2 (en) | 2014-06-17 | 2023-07-18 | GW Research Limited | Use of cannabinoids in the treatment of epilepsy |
US10603288B2 (en) | 2014-06-17 | 2020-03-31 | GW Research Limited | Use of cannabinoids in the treatment of epilepsy |
US9474726B2 (en) | 2014-06-17 | 2016-10-25 | Gw Pharma Limited | Use of cannabinoids in the treatment of epilepsy |
US11963937B2 (en) | 2014-06-17 | 2024-04-23 | GW Research Limited | Use of cannabinoids in the treatment of epilepsy |
US9949937B2 (en) | 2014-06-17 | 2018-04-24 | Gw Pharma Limited | Use of cannabinoids in the treatment of epilepsy |
US9956183B2 (en) | 2014-06-17 | 2018-05-01 | Gw Pharma Limited | Use of cannabinoids in the treatment of epilepsy |
US11154516B2 (en) | 2014-06-17 | 2021-10-26 | GW Research Limited | Use of cannabinoids in the treatment of epilepsy |
WO2015193667A1 (en) * | 2014-06-17 | 2015-12-23 | Gw Pharma Limited | Use of cannabinoids in the treatment of epilepsy |
US9956185B2 (en) | 2014-06-17 | 2018-05-01 | Gw Pharma Limited | Use of cannabinoids in the treatment of epilepsy |
US9956186B2 (en) | 2014-06-17 | 2018-05-01 | Gw Pharma Limited | Use of cannabinoids in the treatment of epilepsy |
US11147776B2 (en) | 2014-06-27 | 2021-10-19 | GW Research Limited | 7-OH-cannabidiol (7-OH-CBD) and/or 7-OH-cannabidivarin (7-OH-CBDV) for use in the treatment of epilepsy |
US11793770B2 (en) | 2014-06-27 | 2023-10-24 | GW Research Limited | 7-OH-cannabidiol (7-OH-CBD) and/or 7-OH-cannabidivarin (7-OH-CBDV) for use in the treatment of epilepsy |
US10966939B2 (en) | 2014-10-14 | 2021-04-06 | GW Research Limited | Use of cannabinoids in the treatment of epilepsy |
US10111840B2 (en) | 2014-10-14 | 2018-10-30 | Gw Pharma Limited | Use of cannabinoids in the treatment of epilepsy |
US10849860B2 (en) | 2014-10-14 | 2020-12-01 | GW Research Limited | Use of cannabinoids in the treatment of epilepsy |
US11633369B2 (en) | 2014-10-14 | 2023-04-25 | GW Research Limited | Use of cannabinoids in the treatment of epilepsy |
US11065209B2 (en) | 2014-10-14 | 2021-07-20 | GW Research Limited | Use of cannabidiol in the treatment of epilepsy |
US10092525B2 (en) | 2014-10-14 | 2018-10-09 | Gw Pharma Limited | Use of cannabinoids in the treatment of epilepsy |
US11096905B2 (en) | 2014-10-14 | 2021-08-24 | GW Research Limited | Use of cannabinoids in the treatment of epilepsy |
EP3735964A1 (en) | 2014-10-14 | 2020-11-11 | GW Research Limited | Use of cannabinoids in the treatment of epilepsy |
US11400055B2 (en) | 2014-10-14 | 2022-08-02 | GW Research Limited | Use of cannabidiol in the treatment of epilepsy |
US10765643B2 (en) | 2014-10-14 | 2020-09-08 | GW Research Limited | Use of cannabidiol in the treatment of epilepsy |
US11154517B2 (en) | 2014-10-14 | 2021-10-26 | GW Research Limited | Use of cannabinoids in the treatment of epilepsy |
US11446258B2 (en) | 2014-10-14 | 2022-09-20 | GW Research Limited | Use of cannabinoids in the treatment of epilepsy |
US10137095B2 (en) | 2014-10-14 | 2018-11-27 | Gw Pharma Limited | Use of cannabinoids in the treatment of epilepsy |
US10918608B2 (en) | 2014-10-14 | 2021-02-16 | GW Research Limited | Use of cannabidiol in the treatment of epilepsy |
US10709673B2 (en) | 2014-10-14 | 2020-07-14 | GW Research Limited | Use of cannabinoids in the treatment of epilepsy |
US10709674B2 (en) | 2014-10-14 | 2020-07-14 | GW Research Limited | Use of cannabinoids in the treatment of epilepsy |
US10709671B2 (en) | 2015-06-17 | 2020-07-14 | GW Research Limited | Use of cannabinoids in the treatment of epilepsy |
US11357741B2 (en) | 2015-06-17 | 2022-06-14 | GW Research Limited | Use of cannabinoids in the treatment of epilepsy |
US12064399B2 (en) | 2015-06-17 | 2024-08-20 | Jazz Pharmaceuticals Research Uk Limited | Use of cannabinoids in the treatment of epilepsy |
US11684598B2 (en) | 2015-08-10 | 2023-06-27 | GW Research Limited | Use of cannabinoids in the treatment of epilepsy |
US11147783B2 (en) | 2015-08-10 | 2021-10-19 | GW Research Limited | Use of cannabinoids in the treatment of epilepsy |
US10583096B2 (en) | 2016-03-31 | 2020-03-10 | GW Research Limited | Use of cannabinoids in the treatment of epilepsy |
US11351152B2 (en) | 2016-06-15 | 2022-06-07 | India Globalization Capital, Inc. | Method and composition for treating seizure disorders |
US10537592B2 (en) | 2016-06-29 | 2020-01-21 | CannScience Innovations Inc. | Decarboxylated cannabis resins, uses thereof and methods of making same |
US10143706B2 (en) | 2016-06-29 | 2018-12-04 | Cannscience Innovations, Inc. | Decarboxylated cannabis resins, uses thereof and methods of making same |
US10383892B2 (en) | 2016-06-29 | 2019-08-20 | CannScience Innovations Inc. | Decarboxylated cannabis resins, uses thereof and methods of making same |
US11229612B2 (en) | 2016-07-01 | 2022-01-25 | GW Research Limited | Parenteral formulations |
US12064398B2 (en) | 2016-07-01 | 2024-08-20 | Jazz Pharmaceuticals Research Uk Limited | Parenteral formulations |
US11291631B2 (en) | 2016-07-01 | 2022-04-05 | GW Research Limited | Oral cannabinoid formulations |
US11065227B2 (en) | 2016-08-25 | 2021-07-20 | GW Research Limited | Use of cannabinoids in the treatment of multiple myeloma |
US11679087B2 (en) | 2016-12-16 | 2023-06-20 | GW Research Limited | Use of cannabinoids in the treatment of Angelman syndrome |
US11426362B2 (en) | 2017-02-17 | 2022-08-30 | GW Research Limited | Oral cannabinoid formulations |
US11806319B2 (en) | 2018-01-03 | 2023-11-07 | GW Research Limited | Pharmaceutical composition comprising a cannabinoid |
US11865102B2 (en) | 2018-04-27 | 2024-01-09 | GW Research Limited | Cannabidiol preparations and its uses |
WO2020225540A1 (en) | 2019-05-03 | 2020-11-12 | GW Research Limited | Use of cannabidiol in the treatment of tuberous sclerosis complex |
US11160795B2 (en) | 2020-02-27 | 2021-11-02 | GW Research Limited | Methods of treating tuberous sclerosis complex with cannabidiol and everolimus |
US11406623B2 (en) | 2020-02-27 | 2022-08-09 | GW Research Limited | Methods of treating tuberous sclerosis complex with cannabidiol and everolimus |
WO2022017936A1 (en) * | 2020-07-20 | 2022-01-27 | GW Research Limited | Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to structural abnormalities of the brain |
WO2022017909A1 (en) * | 2020-07-20 | 2022-01-27 | GW Research Limited | Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to structural abnormalities of the brain |
US11160757B1 (en) | 2020-10-12 | 2021-11-02 | GW Research Limited | pH dependent release coated microparticle cannabinoid formulations |
WO2022180379A1 (en) | 2021-02-25 | 2022-09-01 | GW Research Limited | Use of cannabidiol and clobazam in the treatment of childhood-onset epilepsy syndromes |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20190247324A1 (en) | One or a Combination of Phyto-Cannabinoids in the Treatment of Epilepsy | |
AU2011234225B2 (en) | Use of the phytocannabinoid cannabidivarin (CBDV) in the treatment of epilepsy | |
AU2012314129B2 (en) | A pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD) | |
EP2661263A1 (en) | Use of the phytocannabinoid cannabidiol (cbd) in combination with a standard anti-epileptic drug (saed) in the treatment of epilepsy | |
AU2012204800A1 (en) | Use of the phytocannabinoid cannabidiol (CBD) in combination with a standard anti-epileptic drug (SAED) in the treatment of epilepsy | |
GB2479153A (en) | Use of the phytocannabinoid cannabidivarin (CBDV) in the treatment of epilepsy |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 201080031065.2 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 10734541 Country of ref document: EP Kind code of ref document: A1 |
|
DPE1 | Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2766082 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2012516867 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2012/000257 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2010267775 Country of ref document: AU Ref document number: 804/DELNP/2012 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2010734541 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: A201201092 Country of ref document: UA |
|
ENP | Entry into the national phase |
Ref document number: 20127003123 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2012103603 Country of ref document: RU Ref document number: 12019374 Country of ref document: CO |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112012000076 Country of ref document: BR Kind code of ref document: A2 |
|
ENP | Entry into the national phase |
Ref document number: 2010267775 Country of ref document: AU Date of ref document: 20100629 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13380305 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: 112012000076 Country of ref document: BR Kind code of ref document: A2 Effective date: 20120103 |